BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Apart from targeting the BCR–Abl oncoprotein and c‐KIT (CD117), which are driving kinases in CML and GISTs, respectively, imatinib also blocks PDGFRβ 51.